TNFRSF17 and Miyoshi myopathy: In an MM mouse model, a small oral GS inhibitor (GSI) LY3039478 induced an increase of BCMA expression on MM cells by inhibiting the release of sBCMA in peripheral blood, improving the efficacy of adoptive T-cell therapy targeting BCMA.